Japan PMDA Medical Device Approval: The Complete Guide

Why Japan Matters for Medical Device Companies

Japan is the world's third-largest medical device market, valued at approximately $30 billion annually and trailing only the United States and the European Union. It is a single-payer universal healthcare system with 125 million people, an aging population that is driving demand for advanced medical technologies, and a government that is actively working to attract innovative medical devices through regulatory reforms.

Yet Japan remains one of the most misunderstood regulatory markets. Many manufacturers approach it assuming the process will resemble FDA clearance or CE marking. It does not. Japan has its own classification system, its own approval pathways, its own quality management system ordinance, its own clinical trial requirements, and a unique market authorization structure that requires a domestic entity to hold the marketing authorization. The reimbursement system — which determines whether hospitals can afford to buy your device — operates through a national health insurance pricing mechanism that is entirely distinct from the US or European models.

The regulatory framework is governed primarily by the Pharmaceuticals and Medical Devices Act (PMD Act, also known as the "Yakuki-ho"), which replaced the old Pharmaceutical Affairs Law (PAL) in November 2014. The PMD Act introduced significant structural changes, including the separation of marketing authorization from manufacturing, the creation of new approval pathways, and stronger post-market surveillance requirements.

This guide covers the complete regulatory landscape for medical devices in Japan: the regulatory bodies, device classification, approval pathways, quality management system requirements, clinical trial rules, the marketing authorization holder structure, reimbursement, post-market obligations, and practical guidance for foreign manufacturers entering the Japanese market.

Regulatory Bodies: MHLW and PMDA

Two organizations share responsibility for medical device regulation in Japan. Understanding which body does what is essential for navigating the system.

Ministry of Health, Labour and Welfare (MHLW)

The MHLW is Japan's cabinet-level ministry responsible for healthcare policy, pharmaceutical regulation, and public health. In the medical device context, the MHLW is the ultimate regulatory authority. It sets the laws, issues ministerial ordinances, defines device classifications, and grants marketing approvals for the highest-risk devices (Class IV and certain Class III devices).

Key MHLW functions for medical devices:

• Enacts and amends the PMD Act and associated ordinances
• Issues MHLW Ministerial Ordinances (including MO 169 for QMS)
• Grants Shonin (marketing approval) for Class IV and certain Class III devices
• Designates Registered Certification Bodies (RCBs)
• Sets national health insurance reimbursement prices
• Oversees post-market safety measures and recalls

Pharmaceuticals and Medical Devices Agency (PMDA)

The PMDA is the agency that does the day-to-day regulatory work. It was established in 2004 and serves a role analogous to what the FDA's CDRH does in the United States — reviewing applications, conducting consultations, inspecting manufacturing sites, and monitoring post-market safety signals. However, unlike the FDA, the PMDA does not make the final approval decision for the highest-risk devices. It reviews and makes recommendations, but the MHLW itself issues the formal approval for Shonin applications.

Key PMDA functions:

• Conducts pre-submission consultations (face-to-face scientific advice)
• Reviews Shonin (approval) applications and provides review reports to MHLW
• Conducts QMS conformity assessments (on-site and document-based inspections)
• Reviews clinical trial protocols and data
• Manages post-market safety information (adverse event reports, field safety corrective actions)
• Conducts GMP/QMS inspections of domestic and foreign manufacturing sites
• Operates the relief system for adverse health effects from medical devices

Practical tip: The PMDA consultation system is one of the most valuable features of the Japanese regulatory process. Unlike many regulatory bodies that limit pre-submission interaction, the PMDA offers structured, paid consultation meetings where you can discuss your classification, regulatory pathway, clinical strategy, and testing requirements before you invest in a full submission. Foreign manufacturers who skip PMDA consultations often encounter avoidable delays. Use them.

Device Classification in Japan

Japan classifies medical devices into four classes based on risk, similar in concept to the FDA and EU MDR systems but with its own classification logic and terminology.

The Four Classes

Class	Risk Level	Japanese Term	Regulatory Pathway	Examples
Class I	Lowest risk	一般医療機器 (General Medical Devices)	Todokede (Notification)	Stethoscopes, tongue depressors, medical gauze, surgical drapes
Class II	Low-to-moderate risk	管理医療機器 (Controlled Medical Devices)	Ninsho (Certification) by RCB, or Shonin if no certification standard exists	MRI systems, powered wheelchairs, electronic thermometers, dental alloys, contact lenses
Class III	Moderate-to-high risk	高度管理医療機器 (Specially Controlled Medical Devices)	Ninsho (Certification) by RCB if certification standard exists, or Shonin (Approval) by MHLW	Dialysis equipment, ventilators, absorbable sutures, coronary guidewires, orthopedic implants
Class IV	Highest risk	高度管理医療機器 (Specially Controlled Medical Devices)	Shonin (Approval) by MHLW	Pacemakers, coronary stents, artificial hearts, heart valves

How Classification Works

Device classification in Japan is determined by the MHLW through the Japanese Medical Device Nomenclature (JMDN) system. Each device type is assigned a JMDN code that maps to a specific class and, for Class II and some Class III devices, a certification standard (Ninsho Kijun).

This is a critical difference from the FDA system, where manufacturers self-classify their devices using product codes and classification panels. In Japan, the classification is defined at the regulatory level through JMDN codes, and the existence (or absence) of a certification standard determines whether a device goes through the Ninsho or Shonin pathway.

There are over 4,000 JMDN codes. When a device does not fit an existing JMDN code, the manufacturer must work with the PMDA and MHLW to establish a new classification — a process that adds time and complexity.

Comparison with FDA and EU MDR Classification

Aspect	Japan	FDA (US)	EU MDR
Number of classes	4 (I, II, III, IV)	3 (I, II, III)	4 (I, IIa, IIb, III)
Classification basis	JMDN codes assigned by MHLW	Product codes + classification panels	22 rules in Annex VIII
Who classifies	MHLW (regulatory-determined)	Manufacturer (self-classification)	Manufacturer (self-classification, verified by Notified Body)
Classification changes	Requires MHLW reclassification	FDA reclassification order	Follows rule-based logic

Practical tip: Do not assume that a device classified as Class II by the FDA will also be Class II in Japan. The classification systems are independent. A diagnostic ultrasound system might be Class II in both the US and Japan, but an absorbable wound closure device might be Class II in the US and Class III in Japan. Always confirm the JMDN code and Japanese classification early in your planning.

Approval Pathways: Todokede, Ninsho, and Shonin

Japan has three regulatory pathways for medical devices. The pathway your device follows is determined by its classification and, for Class II and III devices, by whether a certification standard (Ninsho Kijun) exists for that device type.

Todokede (届出) — Notification

Applies to: Class I devices

Todokede is the simplest pathway — a notification submitted to the local prefectural government (not the PMDA or MHLW). It is roughly analogous to FDA Class I device listing, though the specific requirements differ.

The manufacturer or Marketing Authorization Holder (MAH) submits a notification that includes the device name, intended use, specifications, and manufacturing information. There is no pre-market review or approval. Once the notification is submitted, the device can be marketed.

Key requirements:

• Product notification form
• Device description and specifications
• Intended use statement
• Manufacturing site information
• QMS documentation is not subject to PMDA conformity assessment (but the MAH must still maintain a QMS)

Timeline: Days to weeks. This is essentially a registration step, not a review process.

Ninsho (認証) — Certification

Applies to: Class II devices and certain Class III devices for which a certification standard (Ninsho Kijun) exists

Ninsho is a certification pathway where the review is conducted not by the PMDA or MHLW, but by a Registered Certification Body (RCB) — a private third-party organization designated by the MHLW. This is conceptually similar to how Notified Bodies certify devices under the EU MDR, though the specifics differ substantially.

For a device to go through the Ninsho pathway, two conditions must be met:

1. The device must fall under a JMDN code that has an associated certification standard (Ninsho Kijun)
2. The device must conform to that certification standard

Certification standards define the technical requirements — performance, safety, biocompatibility, electrical safety, etc. — that the device must meet. They are published by the MHLW and often reference JIS (Japanese Industrial Standards) or international standards (ISO, IEC).

Key requirements:

• Application submitted to an RCB
• Technical documentation demonstrating conformity to the applicable certification standard
• QMS conformity assessment (conducted by the RCB or PMDA)
• Japanese labeling and instructions for use

Timeline: Typically 4 to 8 months, though this varies by RCB workload and the complexity of the device.

What happens when no certification standard exists? If a Class II or III device falls under a JMDN code without a certification standard, or if the device does not fit any existing JMDN code, the device must go through the Shonin (approval) pathway instead — even if its risk level would otherwise qualify for Ninsho. This is a common source of confusion and delay for foreign manufacturers who assume their Class II device will have a straightforward path.

Shonin (承認) — Approval

Applies to: Class IV devices, Class III devices without a certification standard, and Class II devices without a certification standard

Shonin is the full approval pathway, analogous to an FDA PMA or a high-risk EU MDR conformity assessment. The application is reviewed by the PMDA, which prepares a review report and recommendation, and the final approval decision is made by the MHLW.

Shonin is the most rigorous and time-consuming pathway. It involves a detailed review of safety and efficacy data, typically including clinical data, and a QMS conformity assessment.

Key requirements:

• Application submitted to the PMDA
• Comprehensive technical documentation including device description, intended use, operating principles, and specifications
• Non-clinical testing data (bench testing, biocompatibility, electrical safety, software validation, sterilization validation, etc.)
• Clinical data (Japanese clinical trial data is often required, though there is increasing acceptance of foreign clinical data — see the clinical trials section below)
• QMS conformity assessment
• Risk management documentation
• Japanese labeling and instructions for use

Timeline: 12 to 24 months is typical for a standard Shonin review. Complex or novel devices may take longer. Priority review pathways (Sakigake, DASH) can reduce this — discussed below.

Pathway Decision Tree

Question	If Yes	If No
Is the device Class I?	Todokede (Notification)	Continue below
Is the device Class II or III with a certification standard?	Ninsho (Certification) via RCB	Continue below
Is the device Class II or III without a certification standard, or Class IV?	Shonin (Approval) via PMDA/MHLW	N/A

Comparison of Pathways

Feature	Todokede	Ninsho	Shonin
Device classes	Class I	Class II, some Class III	Class III (no standard), Class IV, some Class II
Reviewing body	Prefectural government	Registered Certification Body (RCB)	PMDA (review) + MHLW (decision)
Clinical data required?	No	Rarely (depends on standard)	Usually yes
QMS conformity assessment?	No	Yes	Yes
Typical timeline	Days–weeks	4–8 months	12–24 months
Approximate fee range	Minimal	¥500K–¥3M	¥3M–¥30M+

Registered Certification Bodies (RCBs)

Registered Certification Bodies play a role in Japan's regulatory system that is in some ways analogous to EU Notified Bodies, but with important differences. RCBs are private third-party organizations designated by the MHLW to review and certify medical devices through the Ninsho pathway.

What RCBs Do

• Review Ninsho applications for Class II and certain Class III devices
• Assess conformity to certification standards (Ninsho Kijun)
• Conduct QMS conformity assessments (or rely on PMDA QMS assessments)
• Issue certification decisions
• Conduct post-certification surveillance

Key RCBs in Japan

Several RCBs operate in Japan. The major ones include:

• Japan Quality Assurance Organization (JQA)
• SGS Japan
• TUV Rheinland Japan
• BSI Group Japan
• Japan Testing Center for Construction Materials (JTCCM)

Selecting an RCB

Not all RCBs cover all device types. Each RCB is designated for specific device categories, and their expertise, review timelines, and fees vary. Key factors in choosing an RCB:

• Scope of designation — Does the RCB cover your device's JMDN code?
• Review timeline — Some RCBs have shorter backlogs than others
• Technical expertise — Does the RCB have experience with your device type?
• QMS assessment capability — Some RCBs conduct their own QMS assessments; others rely on the PMDA's assessment
• Language support — For foreign manufacturers, RCBs with English-language support can ease communication

Practical tip: Engage your RCB early — before your submission is complete. Like Notified Bodies in Europe, RCBs can provide pre-submission guidance on what the certification standard requires and where gaps may exist in your technical file. This is especially valuable for manufacturers entering Japan for the first time.

Marketing Authorization Holder (MAH) Structure

This is one of the most important — and most frequently misunderstood — aspects of the Japanese regulatory system. Japan requires a domestic entity to serve as the Marketing Authorization Holder (MAH) for any medical device sold in the country. Foreign manufacturers cannot directly hold a marketing authorization in Japan.

What Is an MAH?

The MAH (製造販売業者, Seizou Hanbai Gyosha) is the legal entity responsible for placing a medical device on the Japanese market. The MAH holds the marketing authorization (Todokede, Ninsho, or Shonin) and is legally responsible for:

• Overall product safety and quality
• Post-market surveillance
• Adverse event reporting to the PMDA
• Product recalls and corrective actions
• Maintaining the QMS for the device (in coordination with the manufacturer)
• Proper labeling and instructions for use in Japanese
• Compliance with all applicable Japanese regulations

The MAH must be a Japanese legal entity with a physical presence in Japan. It must hold an MAH license (製造販売業許可) issued by the prefectural government, and the license level must match the class of devices being marketed.

MAH License Classes

License Class	Devices Covered	Requirements
Class 1 License (第一種)	Class III and Class IV devices	Most stringent; requires a Quality Assurance Manager (QA Manager) and a Safety Manager, with specific qualification requirements
Class 2 License (第二種)	Class II devices	Requires QA Manager and Safety Manager
Class 3 License (第三種)	Class I devices	Least stringent; requires a Safety Manager

Designated Marketing Authorization Holder (D-MAH)

Since foreign manufacturers cannot hold an MAH license in Japan, they must partner with a Japanese entity that serves as their Designated Marketing Authorization Holder (D-MAH). The D-MAH acts as the regulatory agent and responsible party in Japan.

There are two main models for establishing a D-MAH:

Model 1: Contract with an existing D-MAH service provider. This is the most common approach for foreign manufacturers entering Japan. Several companies specialize in providing D-MAH services, handling regulatory submissions, QMS responsibilities, post-market surveillance, and adverse event reporting on behalf of the foreign manufacturer. This model requires less upfront investment but means you are dependent on a third party for a critical regulatory function.

Model 2: Establish your own Japanese subsidiary. Larger companies or those with long-term strategic commitment to the Japanese market may establish a Japanese subsidiary (K.K. — Kabushiki Kaisha) and obtain the MAH license directly. This gives you full control over regulatory activities but requires significant investment in Japanese personnel, office space, and regulatory infrastructure.

Key Considerations in Choosing a D-MAH

Factor	Contract D-MAH	Own Subsidiary
Setup time	Weeks to months	6–12 months
Upfront cost	Low–moderate (service fees)	High (incorporation, staffing, licensing)
Ongoing cost	Service fees + per-product fees	Employee salaries, office, regulatory maintenance
Control over regulatory activities	Limited — D-MAH manages process	Full control
Speed to market	Faster for first product	Slower initially, faster for subsequent products
Risk	Dependency on third party; D-MAH holds the authorization	Lower long-term risk; you own the authorization
Best for	First entry into Japan; limited product portfolio	Long-term commitment; large product portfolio

Practical tip: The D-MAH relationship is one of the most consequential decisions you will make when entering Japan. The D-MAH holds the marketing authorization — not you. If the relationship deteriorates, transitioning to a new D-MAH requires transferring or re-registering the authorization, which can take months and may leave you without the ability to sell in Japan during the transition. Choose carefully, negotiate transfer provisions in your contract, and understand exactly what responsibilities the D-MAH is taking on versus what remains with you.

D-MAH Setup Process: Step by Step

For foreign manufacturers entering Japan, the practical setup of a D-MAH relationship involves several distinct steps:

Step 1: Identify and evaluate D-MAH candidates. Research established D-MAH service providers. Key evaluation criteria include: the D-MAH's license class (must match your device class — a Class 2 license holder cannot serve as D-MAH for a Class III device), their experience with your device category, their regulatory team's capacity, their track record with the PMDA, and their fee structure. Major D-MAH service providers in Japan include companies such as PAL International, Micren Healthcare, ICST Corporation, and the Japan offices of global regulatory consultancies.

Step 2: Negotiate the D-MAH agreement. The contract should explicitly address: scope of regulatory services, fee structure (retainer plus per-product fees versus all-inclusive), intellectual property protections, data ownership, transition and termination provisions (including a clause requiring the D-MAH to cooperate in transferring the marketing authorization to a successor D-MAH), timelines and performance commitments, liability allocation, and confidentiality obligations.

Step 3: D-MAH personnel requirements. The D-MAH must have the following qualified personnel on staff:

• General Manager (MAH Supervisor / Sogo Sekininsha) — Overall oversight of quality and safety management
• Quality Manager (GQP Manager / Hinshitsu Hoshoo Sekininsha) — Responsible for quality assurance under the GQP (Good Quality Practice) ordinance
• Safety Manager (GVP Manager / Anzen Kanri Sekininsha) — Responsible for post-market safety management under the GVP (Good Vigilance Practice) ordinance

These personnel must meet specific qualification requirements defined by MHLW ordinance, including relevant education and professional experience in pharmaceutical or medical device affairs.

Step 4: Foreign Manufacturer Establishment Registration (FMER). Before a product application can be submitted, the foreign manufacturer must register its manufacturing facilities with the MHLW via the PMDA. This is a prerequisite — you cannot submit a Ninsho or Shonin application until your manufacturing sites are registered.

Foreign Manufacturer Establishment Registration (FMER)

FMER (also referred to as Foreign Manufacturer Registration, or FMR) is the process by which foreign manufacturing sites are registered with the Japanese regulatory authorities. It is a mandatory step for any foreign manufacturer intending to supply medical devices to the Japanese market.

Which facilities must be registered? All foreign facilities involved in:

• Product design and development
• Primary manufacturing (component fabrication, assembly)
• Sterilization
• Final product release and testing

Each facility at a distinct physical address requires a separate FMER registration. Contract manufacturers and contract sterilizers used by the foreign manufacturer must also be registered.

Required documents for FMER application:

• FMER application form
• Business Number Registration Form (to obtain a Gyosha number — the unique business identifier used throughout the Japanese regulatory system)
• Self-declaration of medical condition (Someisho) from the senior manager of the manufacturing facility
• Personal history of the responsible manufacturing facility person
• Facility documentation: photographs, drawings, floor plans showing the buildings and areas within the scope of registration
• Description of the manufacturing operations conducted at the facility

Who submits the FMER application? The FMER application is submitted by the MAH or D-MAH on behalf of the foreign manufacturer. The foreign manufacturer cannot submit directly.

Timeline: FMER processing typically takes 1 to 3 months.

Certificate validity: The FMER certificate is valid for five years. The MHLW recommends beginning the renewal process at least five months before the certificate's expiration date. If the FMER certificate lapses, you cannot legally supply devices manufactured at that facility to the Japanese market until it is renewed.

Practical tip: Begin the FMER process early — it is on the critical path. Your Ninsho or Shonin application cannot be submitted until the FMER is in place for all relevant manufacturing sites. If you use contract manufacturers or contract sterilizers, ensure they are willing to cooperate with the registration process, as their facility information is required. Also note that changes to manufacturing sites after FMER registration (such as facility relocation or major renovations) may require an updated registration.

QMS Requirements: MHLW Ordinance 169

Japan's quality management system requirements for medical devices are defined in MHLW Ministerial Ordinance No. 169 (MO 169), formally titled the "Ordinance on Standards for Manufacturing Control and Quality Control of Medical Devices and In Vitro Diagnostics." MO 169 is based on ISO 13485 but includes Japan-specific additions that manufacturers must address.

MO 169 vs. ISO 13485

The core structure of MO 169 mirrors ISO 13485:2016. If your QMS already conforms to ISO 13485, you are most of the way there. However, MO 169 adds several Japan-specific requirements:

Requirement	ISO 13485	MO 169 (Japan)
QMS structure	ISO 13485:2016 full requirements	ISO 13485:2016 + additional Japan-specific clauses
Biological safety evaluation	Referenced but not prescribed in detail	Specific biological safety evaluation requirements for devices with body contact
Registered manufacturing sites	Not explicitly required	All manufacturing sites must be registered with PMDA
QMS conformity assessment	Third-party audit	PMDA or RCB conformity assessment required for each product application
Marketing Authorization Holder responsibilities	Not applicable	MAH-specific quality and safety management responsibilities
Product-specific QMS documentation	General requirements	May require product-specific QMS documentation tied to each Ninsho or Shonin application
Change management	General change control requirements	Stricter change notification requirements; some changes require regulatory notification or re-assessment

QMS Conformity Assessment Process

Unlike the FDA system (where QMS compliance is assessed through periodic facility inspections) or the EU system (where Notified Bodies conduct QMS audits as part of conformity assessment), Japan's QMS assessment is tied to each individual product application.

When you submit a Ninsho or Shonin application, a QMS conformity assessment is conducted as part of the review. This assessment evaluates:

1. The MAH's quality system — Quality management, safety management, post-market surveillance processes
2. The manufacturer's quality system — Design and development, production, process validation, inspection and testing
3. Registered manufacturing sites — All sites involved in manufacturing, sterilization, and final release must be registered and assessed

The QMS assessment may be conducted as:

• A document-based review (desk audit) for lower-risk devices or when a recent PMDA QMS assessment exists for the same manufacturing site
• An on-site inspection by the PMDA for higher-risk devices, new manufacturing sites, or when concerns arise from the document review

MDSAP and Japan's QMS Requirements

Japan is a participating member of the Medical Device Single Audit Program (MDSAP). An MDSAP audit that includes Japan can satisfy certain QMS assessment requirements, potentially reducing the need for a separate PMDA on-site inspection.

However, MDSAP acceptance in Japan comes with nuances:

• MDSAP can support the QMS conformity assessment but does not automatically replace it
• The PMDA may still require additional information or inspections beyond what MDSAP covers
• Japan-specific requirements in MO 169 that go beyond ISO 13485 must still be addressed
• The MDSAP Auditing Organization must be recognized for the Japan scope

Practical tip: If you already hold an MDSAP certificate with Japan scope, present it early in the regulatory process. It can significantly streamline the QMS conformity assessment and may eliminate the need for an on-site PMDA inspection. But do not assume it is a substitute — confirm with the PMDA or your RCB exactly how your MDSAP certificate will be accepted for your specific product application.

QMS Certificate of Conformance: Validity and Renewal

Upon successful completion of a QMS conformity assessment, the MAH or manufacturer is issued a Certificate of QMS Conformance (Kijun Tekigoshou, 基準適合証) by the PMDA or the RCB. Understanding how this certificate works is essential for maintaining market access.

Certificate scope: The certificate is specific to the product group (Seihingun) and the manufacturing facilities assessed. It lists the registered product name, the product group designation, and the manufacturing facility or facilities covered.

Validity period: QMS Certificates of Conformance are valid for five years from the date of issuance.

Renewal process: The manufacturer must apply for renewal of the QMS certificate before it expires. The MHLW recommends initiating the renewal process at least six months before expiration. Renewal involves a new conformity assessment — either document-based or on-site, depending on the risk level and history. If the certificate lapses, the MAH cannot continue commercial distribution of the affected products.

Important distinction: Device registrations themselves (Shonin or Ninsho approvals) do not expire. However, the MAH must maintain a valid QMS Certificate of Conformance to continue marketing and distributing the device. An expired QMS certificate effectively blocks commercial distribution even though the device's approval remains technically valid.

On-Site vs. Document-Based QMS Assessment: What to Expect

Document-based assessment (desk audit): The PMDA or RCB reviews QMS documentation submitted by the manufacturer without visiting the facility. This is typical for:

• Lower-risk devices (Class II)
• Facilities that have a recent, valid QMS certificate from a prior product assessment
• Facilities with a clean MDSAP audit report that includes Japan scope
• Renewal assessments where no significant changes have occurred

On-site inspection: The PMDA dispatches inspectors to the manufacturing facility. This is more likely for:

• Class III and Class IV devices (especially new approvals)
• New manufacturing facilities not previously inspected by the PMDA
• Facilities where document review raises concerns or questions
• Situations where significant changes to the manufacturing process have occurred since the last assessment

What on-site PMDA inspections cover: PMDA inspectors evaluate compliance with MO 169 across the full quality system, with particular attention to:

• Design and development controls (especially for new devices)
• Production and process controls, including process validation
• Purchasing and supplier management
• Corrective and preventive action (CAPA) systems
• Complaint handling and adverse event reporting processes
• Document and record control
• Management review
• Japan-specific requirements, including biological safety evaluation procedures and registered manufacturing site controls

Duration: On-site PMDA inspections of foreign facilities typically take 2 to 4 days. The PMDA inspection team usually includes 2 to 3 inspectors. For foreign facility inspections, the PMDA may conduct the inspection in English, though having Japanese-speaking quality personnel available is strongly recommended.

Costs: The QMS conformity assessment fee is billed separately from the product application fee. For on-site inspections of foreign facilities, the manufacturer bears the travel expenses for the PMDA inspection team in addition to the assessment fee. These travel costs can be substantial — particularly for facilities outside Asia — and should be budgeted as a line item.

Clinical Trial Requirements

Clinical data requirements in Japan have historically been one of the most significant barriers for foreign medical device manufacturers. For many years, Japan required Japanese clinical trial data for most Class III and IV devices, even when extensive clinical data from US or European studies was available. This has changed meaningfully over the past decade, though the situation remains more nuanced than a simple "foreign data is now accepted."

When Clinical Data Is Required

Pathway	Clinical Data Typically Required?	Notes
Todokede (Class I)	No	No pre-market review
Ninsho (Class II, some III)	Rarely	Only if the certification standard specifically requires clinical data
Shonin (Class III without standard, Class IV)	Usually yes	Especially for novel devices, implantables, and life-sustaining devices

Japanese Good Clinical Practice (J-GCP)

Clinical trials for medical devices in Japan must comply with the MHLW's Good Clinical Practice standards (J-GCP), formally defined in MHLW Ministerial Ordinance No. 36. J-GCP is broadly aligned with the international ICH-GCP guidelines and the ISO 14155 standard for clinical investigation of medical devices, but includes Japan-specific requirements:

• Institutional Review Board (IRB) requirements — Japanese IRBs have specific composition and procedural requirements
• Informed consent — Must comply with J-GCP informed consent requirements, which are detailed and specific
• Clinical trial notification — The sponsor must submit a clinical trial notification (Chiken Todokede) to the PMDA before initiating the trial
• PMDA clinical trial consultation — Pre-trial consultation with the PMDA is strongly recommended and, in practice, expected for most medical device trials
• Monitoring and reporting — Specific adverse event reporting timelines and safety monitoring requirements

Acceptance of Foreign Clinical Data

Japan's acceptance of foreign clinical data has improved substantially, driven by regulatory harmonization efforts and the recognition that requiring redundant Japanese trials delayed patient access to innovative devices. The current framework:

Foreign clinical data may be accepted if:

• The clinical trial was conducted under GCP standards equivalent to J-GCP (typically ICH-GCP or ISO 14155)
• The data is relevant to the Japanese population (ethnic sensitivity factors are considered)
• The endpoints and methodology are consistent with PMDA expectations
• The device and its intended use are identical to what will be marketed in Japan

Additional Japanese clinical data may be required if:

• There are concerns about ethnic or racial differences that could affect safety or performance (e.g., differences in body size, anatomy, disease prevalence, or clinical practice patterns between Japanese and Western populations)
• The foreign clinical trial design does not meet PMDA expectations for endpoints, follow-up duration, or sample size
• The device is a novel technology without Japanese clinical experience

The ethnic factor consideration is unique to Japan (and, to a lesser extent, other Asian regulatory markets). The PMDA evaluates whether differences between Japanese and non-Japanese populations — in terms of body habitus, genetic factors, disease epidemiology, or standard of care — could affect the device's safety or performance. For many device types (e.g., orthopedic implants where bone density and body size may differ, or diagnostic devices where disease prevalence varies), the PMDA may require at least a bridging study or confirmatory Japanese clinical data.

Understanding the Ethnic Factors Framework in Detail

The ethnic factors assessment in Japan is rooted in the ICH E5 guideline ("Ethnic Factors in the Acceptability of Foreign Clinical Data"), which was adopted by the ICH Steering Committee in 1998. While ICH E5 was originally developed for pharmaceuticals, the PMDA applies its principles to medical devices as well — particularly for implantable and therapeutic devices where patient anatomy, physiology, or disease characteristics could affect outcomes.

Intrinsic ethnic factors (genetically or physiologically determined) that the PMDA considers for medical devices include:

• Body size and anthropometric differences (e.g., average body weight, bone dimensions, vessel diameters between Japanese and Western populations)
• Bone mineral density differences (relevant for orthopedic implants)
• Skin characteristics and wound healing patterns (relevant for dermal devices and wound care products)
• Genetic polymorphisms affecting drug metabolism (relevant for drug-device combination products)
• Organ size and anatomical variation (relevant for implantable devices designed around Western anatomical data)

Extrinsic ethnic factors (environmentally or culturally determined) include:

• Differences in clinical practice patterns and standard of care between Japan and foreign markets
• Differences in disease prevalence and severity distribution
• Dietary and lifestyle factors that may affect device performance or patient outcomes
• Differences in healthcare delivery systems (e.g., hospital stay duration, follow-up frequency)

When foreign data is likely to be accepted without additional Japanese data:

• Devices where the mechanism of action is not influenced by patient ethnicity (e.g., many diagnostic imaging devices, general surgical instruments with no body-contact performance variability)
• Devices where the foreign clinical trial included a sufficient number of Asian or Japanese patients
• Well-established device categories with extensive global clinical experience showing no ethnic variation in outcomes

When bridging studies or additional Japanese data are likely required:

• Implantable devices designed around Western anatomical data (e.g., joint prostheses, spinal implants, vascular grafts) — the PMDA may require confirmation that sizing and performance are appropriate for the Japanese population
• Drug-eluting devices where the pharmacokinetic profile may differ in Japanese patients
• Devices for conditions with known epidemiological differences between Japanese and Western populations
• Novel devices with limited clinical experience in any population

The bridging study approach: A bridging study is typically a smaller, confirmatory study conducted in Japanese patients to demonstrate that results observed in a foreign pivotal trial are consistent in the Japanese population. It is not a full repeat of the pivotal trial. A well-designed bridging study typically enrolls 30 to 100 Japanese patients (depending on the device and endpoints) and evaluates the same primary endpoints as the foreign study. The PMDA will advise on the appropriate design during clinical trial design consultation.

Recent evolution: The PMDA has significantly modernized its stance on ethnic factors in recent years. As of late 2023, the PMDA issued guidance clarifying that a separate Japanese Phase I study is not required in principle, provided the sponsor conducts a rigorous ethnic sensitivity assessment and can pre-justify safety and tolerability based on existing data. This is a meaningful departure from earlier practice, where a Japanese Phase I study was frequently expected. For medical devices, the practical implication is that the PMDA is increasingly willing to accept foreign clinical data for well-justified cases, but expects manufacturers to proactively address ethnic factors in their submissions rather than ignore them.

Practical tip: Address ethnic factors explicitly in your clinical data strategy — do not leave it to the PMDA to raise. In your PMDA consultation, present a structured ethnic sensitivity analysis that identifies which intrinsic and extrinsic factors are relevant to your device, explains why they do or do not affect expected outcomes, and proposes how you will address any identified gaps. The PMDA responds favorably to applicants who demonstrate they have thought through this issue, and the consultation record will document the PMDA's position, giving you a clear path forward.

Strategies for Clinical Data

1. Include Japanese sites in your global clinical trial. If you are planning a multinational clinical trial, including Japanese investigational sites from the outset eliminates the need for a separate Japanese study. This is the most efficient approach but requires advance planning and PMDA consultation.

2. Conduct a bridging study. If a comprehensive foreign study already exists, a smaller Japanese bridging study — designed to confirm that results are consistent in the Japanese population — may satisfy PMDA requirements without repeating the full trial.

3. Negotiate the clinical data package during PMDA consultation. The PMDA's pre-submission consultation process is the right venue to discuss what clinical data will be required for your specific device. Do not guess — ask.

4. Leverage literature and real-world evidence. For well-established device types with extensive clinical literature, the PMDA may accept published literature as supporting evidence, particularly for devices where foreign and Japanese clinical experience is comparable.

Practical tip: The single most common mistake foreign manufacturers make with Japanese clinical requirements is waiting until after their pivotal trial is complete to consider Japan. By that point, the trial may not include Japanese sites, the endpoints may not align with PMDA expectations, and a separate Japanese study becomes necessary — adding 2 to 4 years and millions of dollars to the timeline. If Japan is in your commercial plan, engage the PMDA before you finalize your clinical trial protocol.

PMDA Consultations

The PMDA offers a structured consultation system that is more formal and more useful than the pre-submission meetings available in many other regulatory jurisdictions. These consultations are paid services, and the PMDA takes them seriously — you will receive substantive scientific and regulatory feedback.

Types of PMDA Consultations

Consultation Type	Purpose	When to Use
Strategy Consultation (RS Consultation)	Discuss overall regulatory strategy, classification, pathway	Early in planning — before investing in testing or clinical trials
Pre-application Consultation	Review draft application, identify deficiencies	After testing is complete but before formal submission
Clinical Trial Design Consultation	Discuss clinical trial protocol, endpoints, sample size	Before finalizing clinical trial protocol
Quality Consultation	Discuss QMS-related questions	When QMS questions arise during application preparation
Priority Review Consultation	Discuss eligibility for priority review (Sakigake, DASH)	When the device may qualify for expedited review

How Consultations Work

1. Submit a consultation request to the PMDA, including your questions, background information, and supporting documentation
2. PMDA assigns a review team that evaluates your materials before the meeting
3. Face-to-face meeting (or video conference for foreign manufacturers) — typically 1 to 2 hours
4. PMDA issues a consultation record summarizing the discussion, the PMDA's position, and any recommendations

Consultation fees typically range from ¥500,000 to ¥3,000,000 depending on the type and complexity.

Language

PMDA consultations are conducted in Japanese. Foreign manufacturers should work with their D-MAH or a regulatory affairs consultant to prepare materials in Japanese and to have Japanese-speaking regulatory professionals present at the meeting. The PMDA has made efforts to improve English-language support, and some consultations can accommodate English-language participants with interpretation, but the core documentation must be in Japanese.

Registration Timeline and Fees

Understanding the realistic timeline and costs for Japanese market entry is critical for business planning. The timeline varies dramatically by pathway and device complexity.

Timeline Estimates

Phase	Todokede	Ninsho	Shonin
D-MAH selection and contracting	1–3 months	1–3 months	1–3 months
PMDA consultation	Not needed	Optional (1–3 months)	Recommended (2–4 months)
Application preparation	1–2 months	3–6 months	6–12 months
Regulatory review	Days–weeks	4–8 months	12–24 months
QMS conformity assessment	Not required	2–6 months (parallel with review)	3–8 months (parallel with review)
Total estimated timeline	1–3 months	8–18 months	18–36 months

Fee Structure

Fees in Japan are paid at multiple stages and to multiple entities. The major cost categories:

Fee Category	Approximate Range	Notes
PMDA consultation fees	¥500K–¥3M per consultation	Varies by consultation type
Ninsho application fee (RCB)	¥500K–¥3M	Varies by RCB and device complexity
Shonin application fee (PMDA)	¥3M–¥30M+	Based on device class and type; higher for novel devices
QMS conformity assessment fee	¥1M–¥10M	Depends on number of manufacturing sites and assessment scope
D-MAH service fees	¥2M–¥10M+ per year	Depends on D-MAH, services included, and number of products
Clinical trial costs (if required)	¥50M–¥500M+	Highly variable; depends on trial scope
Translation and regulatory consultancy	¥2M–¥10M+	Japanese translations of technical documentation, regulatory strategy support

Detailed PMDA Shonin Application Fees

The PMDA publishes an official fee schedule for Shonin applications. Fees vary significantly depending on device class, whether the device is new or generic, and whether clinical investigation data is included. The following table reflects the published PMDA fee structure:

Application Type	PMDA Fee	Approximate USD
Class II — Generic device with approval standard (AS)	¥414,600	~$2,800
Class II — Generic device without clinical investigation/AS	¥1,480,400	~$10,000
Class II — Improved device	¥1,480,400–¥4,404,700	~$10,000–$29,800
Class II — New device with clinical investigation data	¥8,620,500	~$58,200
Class III — Range depending on type	¥414,600–¥8,620,500	~$2,800–$58,200
Class IV — Generic device with approval standard	¥499,700	~$3,400
Class IV — New device with clinical investigation data	¥11,736,000	~$79,300

These are the PMDA application fees only and do not include QMS conformity assessment fees, which are billed separately. Class I devices (Todokede pathway) have no PMDA application fee. For Ninsho pathway devices, the RCB sets its own fees, typically starting at ¥500,000 for straightforward Class II certifications.

PMDA consultation fees are structured separately. The first introductory consultation session (approximately 30 minutes) is offered free of charge. Subsequent formal consultations — including strategy consultations, clinical trial design consultations, and pre-application consultations — are paid services, with fees typically around ¥1,000,000 to ¥3,000,000 depending on the consultation type and complexity. A standard 2-hour consultation meeting costs approximately ¥1,500,000 (~$10,000 USD).

Practical tip: The PMDA fee schedule is updated periodically. Always verify current fees on the PMDA website before budgeting. Fees listed here are based on the most recently published schedule, but revisions may apply. Note also that partial change applications (Ichibu Henko) — required when you modify an already-approved device — carry their own fee categories that are generally lower than new approval fees but still substantial.

Practical tip: Budget for the full cost of market entry, not just the regulatory fees. Translation, D-MAH fees, regulatory consulting, and clinical trial costs (if applicable) often exceed the official PMDA fees by a factor of 5 to 10. A realistic budget for bringing a Class III device through Shonin to Japanese market entry — including D-MAH setup, consultations, application preparation, QMS assessment, and post-approval activities — is typically ¥30M to ¥100M ($200K to $700K USD) for a device that does not require a Japanese clinical trial, and substantially more if a clinical trial is needed.

Sakigake and DASH: Expedited Review Programs

Japan has introduced several programs to accelerate the review of innovative medical devices, driven by a policy goal of reducing the "device lag" — the historical delay between when a device becomes available in the US or Europe and when it reaches the Japanese market.

Sakigake Designation

The Sakigake (先駆け, meaning "pioneer" or "forerunner") designation system was introduced in 2015 as a pilot and formally codified in the 2019 PMD Act revision. It is designed to provide priority review for breakthrough medical devices, particularly those developed in Japan or with significant Japanese involvement.

Eligibility criteria:

• The device treats a serious or life-threatening condition
• There is no existing satisfactory treatment or the device offers significant improvement over existing treatments
• The device is intended to be first introduced in Japan (or simultaneously with other markets)
• There is scientific evidence supporting the expected benefit

Benefits of Sakigake designation:

• Priority PMDA consultation — Access to expedited pre-submission meetings; consultation waiting time reduced from the standard 3+ months to approximately 1 month
• Priority review — Target total review time of 6 months (compared to 12–24 months standard)
• Pre-submission engagement — PMDA assigns a dedicated review partner (a named PMDA reviewer who serves as a concierge throughout the development and review process)
• Pre-submission assessment — PMDA conducts a preliminary assessment of the application before formal submission, identifying potential issues early
• Conditional approval pathway — In some cases, approval based on limited clinical data with post-market commitments

Sakigake Designation: Real-World Examples

Since the Sakigake designation system was extended to medical devices in 2015, a number of devices have received this designation. The following are documented examples of medical devices and regenerative medical products that received Sakigake designation:

Device	Manufacturer	Year Designated	Indication	Status
Titanium Bridge	Nobelpharma	2016	Hinge-type titanium plates for spasmodic dysphonia treatment	Approved December 2017
Tracheal Prosthesis	Daiichi Medical	2017	Polypropylene mesh and collagen sponge for tracheal reconstruction	Post-designation development
Boron Neutron Capture Therapy (BNCT) System	Sumitomo Heavy Industries	2017	Neutron irradiation system for glioblastoma and head/neck cancer	Approved March 2020
UT-Heart	UT-Heart Corporation	2018	Software predicting cardiac resynchronization therapy effectiveness	Post-designation development
Cardiac Repair Patch	Teijin	2018	Bioabsorbable polymeric patch with gelatin membrane for cardiac repair	Post-designation development
CliniMACS CD34 System	Miltenyi Biotec K.K.	2018	CD34+ cell selection system for bone fracture treatment	Post-designation development
Microwave Mammography	Integral Geometry Science Co.	2019	Breast cancer tissue identification using microwave imaging	Post-designation development
Vascular Grafts	Biotube Co.	2019	In vivo tissue-engineered grafts for lower extremity arterial bypass surgery	Post-designation development
Phosphorylated Pullulan Bioadhesive	BioARC Co.	2019	Bioadhesive material for bone defect repair	Post-designation development

Notable conditional approvals under related programs: HeartSheet (Terumo), a skeletal myoblast sheet product for severe heart failure, was granted Japan's first conditional and time-limited approval in September 2015. PMDA required all-case post-market surveillance monitoring and a long-term patient registry. However, after the post-market re-examination period, the MHLW determined in July 2024 that HeartSheet had not demonstrated sufficient efficacy, and full approval was not granted — illustrating that conditional approval carries real risk and that post-market evidence requirements are enforced.

Practical tip: The HeartSheet case is instructive: conditional approval in Japan is not a guarantee of permanent market access. Manufacturers who receive conditional or time-limited approval must invest seriously in the required post-market studies, because the PMDA and MHLW will revoke market access if the evidence does not support continued approval. Plan and budget for post-market evidence generation from the outset.

DASH (Device Acceleration and Strategic Initiative)

The DASH program, introduced by the PMDA, is complementary to Sakigake and focused specifically on reducing device lag. It offers expedited review for medical devices that are already approved in a comparable regulatory jurisdiction (US, EU, or other recognized markets) but not yet available in Japan.

Key features:

• Devices with prior FDA clearance/approval or CE marking may qualify
• Streamlined review process that leverages existing foreign regulatory reviews
• Reduced requirement for duplicative Japanese testing when foreign data is adequate

Other Expedited Mechanisms

Program	Target	Benefit
Sakigake Designation	Breakthrough devices, first-in-Japan	6-month priority review, dedicated PMDA team
DASH	Devices already approved abroad	Leverages foreign regulatory reviews
Priority Review (Yusen Shinsa)	Devices for serious conditions with no alternatives	Expedited PMDA review timeline
Conditional/Term-limited Approval	Devices where long-term data is limited	Approval with post-market data generation requirements

Practical tip: Sakigake and DASH are powerful tools, but they are not automatic. Sakigake requires a formal designation application and is highly competitive. DASH is more accessible for devices with existing foreign approvals, but you must proactively engage the PMDA about eligibility. Discuss these options during your initial PMDA strategy consultation.

JIS Standards and Their Role

Japanese Industrial Standards (JIS) play an important role in Japan's medical device regulatory framework. While Japan has increasingly adopted international standards (ISO, IEC), JIS standards remain relevant and, in some cases, are referenced directly in certification standards (Ninsho Kijun).

JIS vs. International Standards

Japan has made significant progress in harmonizing JIS standards with their international counterparts. Many JIS standards for medical devices are now identical to or technically equivalent to the corresponding ISO or IEC standard. For example:

JIS Standard	Corresponding International Standard	Subject
JIS T 0601-1	IEC 60601-1	Medical electrical equipment — General safety
JIS T 2304	IEC 62304	Medical device software — Lifecycle processes
JIS T 14971	ISO 14971	Risk management for medical devices
JIS T 0993-1	ISO 10993-1	Biological evaluation of medical devices
JIS Q 13485	ISO 13485	Quality management systems for medical devices

When JIS Standards Matter

• Certification standards (Ninsho Kijun) — These often reference JIS standards as the technical requirements for Ninsho pathway devices. Conformity to the cited JIS standard(s) is required for certification.
• Shonin applications — While Shonin applications are not bound to specific JIS standards, compliance with relevant JIS/ISO/IEC standards strengthens the application and can expedite review.
• QMS assessment — JIS Q 13485 (equivalent to ISO 13485) forms the basis of the QMS requirements under MO 169.

Practical Implications

If your device already conforms to the relevant international standards (ISO, IEC), you will typically meet the substance of the corresponding JIS requirements. However, verify carefully — there are cases where JIS standards include Japan-specific deviations or additional requirements not present in the international version. These deviations are becoming less common as harmonization progresses, but they have not been fully eliminated.

Reimbursement: NHI Price Listing

Regulatory approval alone does not guarantee commercial success in Japan. Because Japan operates a universal healthcare system through National Health Insurance (NHI), the reimbursement price assigned to your device by the government directly determines how much hospitals will pay for it — and, consequently, whether your business model works.

How Japanese Reimbursement Works

Japan's NHI system covers virtually the entire population. Healthcare providers (hospitals, clinics) are reimbursed by the NHI system for medical services and devices according to a fee schedule that is revised every two years by the Central Social Insurance Medical Council (Chuikyo), which advises the MHLW.

Medical devices used in procedures are reimbursed through the NHI price list (Tokutei Hoken Iryou Zairyou). To be reimbursed, a device must be listed on this NHI price list with an assigned reimbursement price. Without NHI listing, hospitals must absorb the device cost — which, in practice, means they will not buy it.

Reimbursement Categories: C1 and C2

When a new medical device receives regulatory approval (Shonin or Ninsho), its reimbursement application is evaluated and assigned to a category that determines how the price is set.

Category	Name	Description	Pricing Method
A1	Existing functional category, existing price	Device fits an existing functional category and the current price is adequate	Listed at the existing category price
A2	Existing functional category, price adjustment needed	Device fits an existing functional category but has improved function or cost differences	Price adjusted within the existing category
B	Existing functional category, new subcategory needed	Device is similar to existing devices but sufficiently different to warrant a new subcategory	New subcategory created; price based on comparables with adjustments
C1	New functional category, similar to existing technology	Device creates a new functional category but is based on existing technology	New category created; price based on comparable devices and cost analysis
C2	New functional category, novel technology	Device creates a new functional category and represents a genuinely novel technology	New category created; price based on cost calculation (manufacturing cost + markup)

C1 and C2 are the categories that matter most for innovative devices. If your device is truly novel and does not fit an existing functional category, you will need to apply for C1 or C2 listing.

• C1 is for devices that are new to the Japanese market but based on technology concepts that already exist. The pricing is determined by comparison to similar devices and may include an innovation premium.
• C2 is for genuinely novel devices with no comparable product in Japan. Pricing is based on a cost calculation approach where you submit your manufacturing cost data and the MHLW applies a markup formula.

C1 and C2 in Practice: Pricing Methodology and Real-World Data

Understanding the practical mechanics of C1 and C2 pricing is critical for business planning.

C1 pricing methodology (Similar Function Category Comparison): When a device qualifies for C1, the MHLW identifies the most similar existing functional category and sets the new category's reimbursement price based on the existing category price, adjusted for functional differences. A premium may be applied if the device demonstrates improved clinical performance. Historical data shows that the average premium rate for C1 devices priced via the similar function category comparison method has declined over time — from approximately 10% during 2008–2010 to approximately 3% during 2016–2018. This declining trend reflects increasing pressure on device pricing as more categories become established.

C2 pricing methodology (Cost Accounting): For C2 devices, the manufacturer submits detailed cost data — including raw material costs, manufacturing costs, overhead, distribution costs, and a reasonable profit margin — and the MHLW applies a formula to determine the reimbursement price. The cost accounting method generally produces prices closer to international averages (approximately 0.97 times the Foreign Average Price), while the similar function comparison method tends to produce prices slightly below international averages (approximately 0.92 times the Foreign Average Price).

Innovation premiums: For devices demonstrating exceptional clinical value, three types of surcharge premiums may be applied:

• Innovativeness Premium (Kakushinsei Kassan) — For devices with a novel mechanism and significant clinical utility. Typically 5–30% above the base price.
• Usefulness Premium (Yuuyousei Kassan) — For devices with improved clinical outcomes over existing options. Typically 3–10%.
• Epochal Function Premium (Kakkiteki Kinou Kassan) — The highest premium tier, reserved for genuinely breakthrough devices. This premium has been awarded very rarely — the most notable example being drug-eluting stents (DES), which received an epochal function premium when first introduced to the Japanese market in 2004. Only a handful of devices have received this designation since the current pricing framework was established in 2002.

Timeline from approval to NHI listing: The time from regulatory approval to NHI price listing varies significantly by category:

• C1 devices: Average of 234 days (approximately 8 months) from approval to NHI listing
• C2 devices: Average of 341 days (approximately 11 months) from approval to NHI listing
• Technical fee-only applications: Average of 432 days (approximately 14 months)

Practical example — TAVI (Transcatheter Aortic Valve Implantation): When TAVI devices were first introduced to the Japanese market, they were classified as C2 (novel technology, new functional category). The MHLW created a new functional category and technical fee for the TAVI procedure, with the reimbursement price set through cost accounting. Since 2021, the MHLW has consistently upgraded reimbursement schedules for TAVI procedures, reflecting the technology's growing clinical acceptance and procedural volume in Japan. TAVI illustrates how C2 devices can achieve favorable reimbursement when strong clinical evidence supports their value.

Practical example — MRI-conditional pacemakers and ICDs: When MRI-conditional pacemakers and implantable cardioverter defibrillators (ICDs) were introduced, they initially received premium pricing through a C1 application (new functional category based on existing pacemaker/ICD technology but with the added functionality of MRI compatibility). However, following the April 2018 NHI price revision, these MRI-conditional categories were merged with the standard pacemaker and ICD categories — eliminating the premium. This is an important cautionary example: premium pricing for innovative features may be temporary, as the MHLW may reclassify devices into lower-priced categories once the technology becomes standard.

Foreign Reference Pricing (FRP): Japan's reimbursement pricing has historically used a three-pillar system: functional category comparison, Foreign Average Price (FAP) referencing, and cost accounting. Recent policy shifts have reduced the weight given to prices from markets with higher-than-average prices, particularly the United States and Australia. Manufacturers should be aware that the MHLW is increasingly emphasizing clinical value evidence over international price benchmarking when setting reimbursement prices.

Practical tip: Start your reimbursement strategy at the same time as your regulatory strategy — not after approval. Determine early whether your device will fall into A1/A2, B, C1, or C2. If C1 or C2, prepare a comprehensive health economics dossier alongside your regulatory submission. The data required to justify an innovation premium — including comparative clinical effectiveness data, cost-effectiveness analyses, and evidence of unmet need — takes time to compile. Waiting until after approval to begin reimbursement planning can add 6 to 12 months to your market entry timeline.

NHI Price Application Process

1. Regulatory approval is granted (Shonin or Ninsho)
2. Reimbursement application is submitted to the MHLW, including clinical and economic evidence supporting the requested price and category
3. The Hoken Iryou Zairyou Senmon Soshiki (Medical Device Expert Committee) evaluates the application and recommends a category and price
4. Chuikyo (Central Social Insurance Medical Council) makes the final pricing decision
5. NHI price listing is published — typically in conjunction with the biennial NHI fee schedule revision (April of even-numbered years), though off-cycle listings are possible for high-priority devices

Timeline for Reimbursement

The time from regulatory approval to NHI price listing can range from 2 to 12 months, depending on the category:

• A1/A2 (existing category): 2 to 3 months
• B (new subcategory): 3 to 6 months
• C1 (new category, similar technology): 3 to 6 months
• C2 (new category, novel technology): 6 to 12 months

This means that for C2 devices, the total time from regulatory submission to the point where hospitals can actually purchase your device at a reimbursed price can extend well beyond the regulatory review period.

Biennial Price Revision

Every two years, the MHLW revises the NHI fee schedule, and medical device reimbursement prices are typically adjusted downward. This is a critical business consideration — your device's reimbursement price will decrease over time. The average price reduction in recent revisions has been in the range of 1% to 5% per cycle, though the reduction varies by device category and market dynamics.

Practical tip: Build your Japan business model around the reimbursement price, not your global list price. Many foreign manufacturers discover too late that the NHI price assigned to their device is lower than their global average selling price, making the Japanese market unprofitable at their current cost structure. Model the NHI price early — ideally before you invest in regulatory submissions — and factor in the biennial price reductions over your product lifecycle.

Post-Market Requirements

Japan has extensive post-market requirements that are among the most demanding in the world. These requirements are taken seriously by the MHLW and PMDA, and non-compliance can result in suspension or revocation of marketing authorization.

Post-Market Surveillance (PMS)

The MAH is responsible for conducting ongoing post-market surveillance. The scope and rigor depend on the device class and the terms of the marketing authorization.

Requirement	Class I	Class II	Class III/IV
PMS plan	Recommended	Required	Required
Adverse event reporting	Yes (MAH obligation)	Yes (MAH obligation)	Yes (MAH obligation)
Periodic safety reports	No	May be required	Required
Re-examination (Use-Results Surveys)	No	Rare	Often required for new devices
Re-evaluation	No	Possible	Possible

Adverse Event Reporting

The MAH must report adverse events to the PMDA within defined timelines:

Event Type	Reporting Timeline
Death or serious health consequence, known cause	15 days
Death or serious health consequence, unknown cause	15 days
Malfunction that could lead to death or serious health consequence	30 days
Trend of increasing malfunctions	Upon detection

Re-examination (Saishinsai)

For devices approved through the Shonin pathway — particularly novel devices — the MHLW may impose a re-examination period, typically 3 to 7 years. During this period, the MAH must conduct use-results surveys (a form of post-market clinical follow-up) and submit a re-examination application at the end of the period. The purpose is to confirm the device's safety and efficacy in real-world Japanese clinical use.

This is conceptually similar to FDA post-market study requirements imposed as a condition of approval, but it is more systematic in Japan and applies to a broader range of devices.

Re-evaluation (Saihyouka)

The MHLW can order a re-evaluation of any approved medical device if new safety or efficacy concerns arise. This can result in additional conditions being placed on the marketing authorization, labeling changes, or — in extreme cases — withdrawal of approval.

Quality Management System Maintenance

The MAH must maintain its QMS in compliance with MO 169 on an ongoing basis. Changes to the device, manufacturing process, or manufacturing sites may trigger a requirement for a QMS re-assessment by the PMDA or RCB.

Japan vs. FDA vs. EU MDR: Comparative Overview

Understanding how Japan's system compares to the FDA and EU MDR helps manufacturers plan multi-market strategies.

Feature	Japan (PMD Act)	US (FDA)	EU (MDR)
Regulatory authority	MHLW + PMDA	FDA (CDRH/CBER)	National Competent Authorities + Notified Bodies
Classification system	4 classes (I–IV)	3 classes (I–III)	4 classes (I, IIa, IIb, III)
Lowest-risk pathway	Todokede (Notification)	Exempt / 510(k) for non-exempt Class I/II	Self-declaration (Class I)
Mid-risk pathway	Ninsho (RCB Certification)	510(k)	Notified Body conformity assessment
Highest-risk pathway	Shonin (PMDA/MHLW Approval)	PMA	Notified Body conformity assessment (highest scrutiny)
QMS standard	MO 169 (based on ISO 13485)	QMSR (based on ISO 13485, effective Feb 2026)	ISO 13485 (via harmonized standards)
Domestic representative required?	Yes — MAH (must be Japanese entity)	No (but US Agent required for foreign manufacturers)	Yes — EU Authorized Representative
Clinical data for high-risk devices	Usually required; ethnic factors considered	Usually required for PMA; sometimes for 510(k)	Required; clinical evaluation mandatory for all classes
Acceptance of foreign clinical data	Increasingly accepted; ethnic bridging may be required	Generally accepted if under GCP	Generally accepted if under ISO 14155/GCP
Post-market surveillance	Extensive; re-examination period for novel devices	PMA annual reports; 522 post-market studies	PMS plan, PMCF, PSUR/SSCP
Reimbursement	NHI price listing (government-set price)	Varies by payer (Medicare, private insurance)	Varies by member state (HTA processes)
Average approval time (high-risk)	12–24 months (Shonin)	12–18 months (PMA)	12–18 months (Notified Body review)
Unique device identification	JMDN-based system	UDI (FDA UDI system)	UDI (EU UDI system, EUDAMED)
MDSAP acceptance	Yes (recognized)	Yes (voluntary, reduces inspections)	No (EU is not an MDSAP participant)

Recent Reforms and Regulatory Trends

Japan's medical device regulatory system is not static. Several significant reforms and trends are reshaping the landscape.

PMD Act Revisions

The PMD Act has undergone multiple revisions since its 2014 introduction, with the most significant updates in 2019, 2022, and 2025. Key changes include:

• Codification of Sakigake designation — Formally establishing the expedited review pathway in law (2019 revision)
• Introduction of conditional and term-limited approval — Allowing devices to reach the market with limited data, subject to post-market data generation requirements (2019 revision)
• Strengthened post-market surveillance — Enhanced reporting requirements and PMDA post-market monitoring capabilities
• Digital health and SaMD framework — Updated guidance for software as a medical device, reflecting global trends
• International harmonization — Continued alignment with IMDRF work items and greater acceptance of foreign data

2025 PMD Act Amendments

The most recent major revision to the PMD Act was enacted on May 14, 2025, with phased implementation over three years (full effect by May 2027). These amendments introduce several changes that directly affect medical device manufacturers:

Quality and safety personnel changes: The 2025 amendments empower the MHLW to mandate changes in responsible personnel (Sekinin Yakuin — board members or officers responsible for quality and safety) at the MAH if quality issues arise and the Minister determines that improvement cannot be reasonably expected without personnel changes. This is a significant enforcement tool that gives regulators direct authority over MAH leadership.

Adverse event collection systems: MAHs are now required to establish more comprehensive adverse event collection systems, going beyond the existing GVP (Good Vigilance Practice) obligations. The amendments strengthen the expectation that MAHs proactively collect and analyze safety signals, not merely respond to reported events.

Supply chain management: The amendments introduce a new Supply System Manager (供給体制管理者) role within the MAH organization. This person is responsible for creating supply plans, coordinating with manufacturers and wholesalers, and notifying the MHLW of supply disruptions. This requirement reflects lessons learned from medical device supply shortages and takes effect within two years of enactment (by May 2027).

Expanded conditional approval pathways: Beginning in May 2026, the scope of conditional registration approval is expanded to cover more medical devices and in vitro diagnostics. Devices with strong clinical evidence but limited treatment alternatives may qualify for conditional approval, allowing earlier patient access while post-market evidence accumulates. This aligns with the government's broader goal of reducing device lag.

Pediatric and rare disease support: The revised PMD Act establishes a dedicated fund for developing treatments — including medical devices — for pediatric and rare disease populations. This creates potential incentives for manufacturers developing devices for underserved patient groups.

Advertising enforcement: The amendments introduce a surcharge penalty system for violations of medical device advertising regulations. Violators face penalties equivalent to 4.5% of the sales value of the affected products during the violation period, with a 50% reduction available for voluntary self-reporting.

PMDA Capacity Expansion

The MHLW increased its fiscal 2025 budget by more than $3 billion (approximately ¥450 billion), with significant allocations for regulatory infrastructure:

• Enhanced training for GMP and QMS inspectors
• Recruitment of additional PMDA reviewers to reduce review backlogs
• Greater flexibility in reviewing submissions containing English-language documentation (a meaningful improvement for foreign manufacturers)
• Expansion of the PMDA's U.S. presence from one to two representatives based in Washington, D.C., facilitating interaction with US-based manufacturers and the FDA

EMC Standards Transition (JIS T 0601-1-2)

Effective February 25, 2026, all medical devices manufactured and marketed in Japan must comply with the updated JIS T 0601-1-2:2023 electromagnetic compatibility standard. Devices manufactured before this date may continue using the previous JIS T 0601-1-2:2018 standard, but any device produced on or after February 25, 2026 must meet the updated requirements. Manufacturers should plan their EMC testing and documentation updates accordingly.

IDATEN Framework for AI/ML Medical Devices

The PMDA is expanding the IDATEN (Improvement Design within Approval Timeline and Efficacy Evaluation for AI/ML-based Software as a Medical Device) framework. This framework is designed specifically for AI-powered medical devices that learn and improve after deployment. Under IDATEN, pre-approved modifications to the AI algorithm can proceed without requiring a new approval application for each software update — provided the modifications fall within the pre-approved change protocol. This is one of the most progressive adaptive AI regulatory frameworks globally and positions Japan as a relatively favorable market for AI/ML-based medical devices.

Two-Step Approval for Diagnostic SaMD

A new two-step approval pathway has been introduced for diagnostic software as a medical device (SaMD):

• Stage I approval is granted based on measurement performance data (analytical validation), allowing the software to enter the market
• Stage II approval follows after clinical evidence accumulates in real-world settings, confirming diagnostic accuracy and clinical utility

This staged approach allows diagnostic SaMDs to reach patients faster while generating the clinical evidence needed for full validation.

Software as a Medical Device (SaMD)

Japan has been actively updating its regulatory framework for SaMD, including:

• Revised classification criteria for standalone software
• New guidance on AI/ML-based medical devices
• A regulatory sandbox program (Regulatory Science Strategy Consultation) for novel digital health technologies
• Alignment with the IMDRF SaMD framework

Reducing Device Lag

The "device lag" — the delay between when a device becomes available in the US/EU and when it reaches Japan — has been a persistent policy concern. Government initiatives to reduce it include:

• Sakigake and DASH programs (described above)
• Increased PMDA reviewer staffing and training
• Greater acceptance of foreign clinical data
• Harmonization of review standards with international norms

Data shows progress: the median device lag has decreased from approximately 3 years in the early 2010s to 1 to 2 years in the mid-2020s for many device types, though significant lag remains for some categories.

Pharmacoequivalence for Combination Products

Japan has introduced streamlined pathways for combination products (drug-device combinations) that align more closely with international approaches, reducing duplicative reviews between the drug and device regulatory tracks.

Practical Guide for Foreign Manufacturers

Entering the Japanese market is a multi-year, multi-stakeholder process. Here is a practical roadmap based on the realities of the system.

Step 1: Assess the Opportunity (Month 0–3)

• Determine device classification. Identify the JMDN code for your device and confirm the Japanese class. Engage a Japanese regulatory consultant or your prospective D-MAH.
• Determine the regulatory pathway. Is it Todokede, Ninsho, or Shonin? Does a certification standard exist?
• Model the reimbursement. Research the NHI functional category and estimate the likely reimbursement price. Determine whether the NHI price supports your business case.
• Assess clinical data needs. Will Japanese clinical data be required? Can your existing clinical data be leveraged?
• Budget realistically. Factor in D-MAH fees, PMDA fees, translation, consulting, and potential clinical trial costs.

Step 2: Establish Your D-MAH (Month 3–6)

• Select a D-MAH — either a contract D-MAH service provider or begin establishing a Japanese subsidiary.
• Negotiate the D-MAH agreement — clarify responsibilities, fees, IP protections, and transition/termination provisions.
• Ensure the D-MAH holds the appropriate license class for your device.

Step 3: PMDA Consultation (Month 6–12)

• Request a strategy consultation (RS Consultation) to discuss classification, pathway, clinical data requirements, and testing strategy.
• If clinical trials are needed, request a clinical trial design consultation.
• Document PMDA feedback and incorporate it into your regulatory plan.

Step 4: Prepare the Submission (Month 12–24)

• Prepare the technical documentation in Japanese (or have it translated). This includes device description, specifications, non-clinical test data, clinical data, risk management, labeling, and instructions for use.
• Ensure QMS readiness — confirm that your manufacturing sites are registered and that your QMS meets MO 169 requirements. If you have MDSAP certification with Japan scope, prepare to present it.
• Prepare the QMS conformity assessment documentation — this is a separate submission from the product application but is reviewed in parallel.

Step 5: Submit and Review (Month 18–36 for Shonin)

• Submit the application to the RCB (for Ninsho) or the PMDA (for Shonin).
• Respond to review questions promptly — delays in responding are one of the most common causes of extended review timelines. Work closely with your D-MAH to ensure responses are in Japanese and technically accurate.
• QMS conformity assessment runs in parallel with the application review. Schedule any necessary on-site inspections early.

Step 6: Post-Approval Activities (After Approval)

• Apply for NHI price listing — work with your D-MAH to submit the reimbursement application and support the pricing evaluation.
• Establish post-market surveillance — ensure your D-MAH has PMS systems in place for adverse event reporting, use-results surveys (if applicable), and periodic safety reporting.
• Commercial launch — once the NHI price is listed, hospitals can begin purchasing the device.

Common Mistakes to Avoid

1. Underestimating the D-MAH relationship. The D-MAH holds your marketing authorization. Choose carefully and negotiate thoroughly.

2. Ignoring reimbursement until after approval. If the NHI price does not support your business model, regulatory approval is commercially meaningless.

3. Assuming foreign clinical data will be accepted without discussion. Always confirm with the PMDA through a consultation before committing to a clinical data strategy.

4. Translating technical documents as an afterthought. Poor-quality Japanese translations cause review delays. Use regulatory-specialized translators who understand medical device terminology.

5. Skipping PMDA consultations. These are not optional meetings — they are the mechanism through which you avoid costly surprises. Use them.

6. Applying Japanese timelines to US/EU expectations. Japan's regulatory process takes longer than many manufacturers expect. Build realistic timelines into your business plan from day one.

7. Neglecting post-market obligations. Japan's post-market requirements are substantive and enforced. The re-examination period for novel devices requires active data collection and reporting for years after approval.

8. Overlooking change management. Device modifications after approval in Japan may trigger regulatory notification requirements, re-assessment, or even a new application. Your change control process must account for Japan-specific requirements.

Key Takeaways

Japan is one of the world's most important medical device markets, but entering it requires a fundamentally different approach from the US or EU. The regulatory system is rigorous, the MAH structure imposes unique requirements on foreign manufacturers, clinical data expectations must be addressed proactively, and the reimbursement system directly controls your commercial viability.

The manufacturers who succeed in Japan are those who plan early, invest in the right partnerships (especially the D-MAH relationship), use the PMDA consultation system, and treat regulatory approval and reimbursement as parallel workstreams rather than sequential ones.

The regulatory landscape is improving. Sakigake and DASH are reducing device lag. Foreign clinical data acceptance is expanding. MDSAP is streamlining QMS assessments. The PMDA is becoming more accessible and more aligned with international standards. But Japan will always require Japan-specific preparation — there are no shortcuts.

Start early, budget realistically, use the consultation system, and respect the process. The Japanese market rewards companies that take it seriously.